Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
86.84
+0.22 (+0.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
August 16, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
August 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MODERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Moderna, Inc. and Encourages Investors to Contact the Firm
August 14, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Moderna and Coursera Launch Free Course on mRNA Technology
August 14, 2024
Via
ACCESSWIRE
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 01, 2024
Via
ACCESSWIRE
David Rubenstein Joins Moderna's Board of Directors
July 23, 2024
Via
ACCESSWIRE
Stockholder Alert: Robbins LLP Informs Moderna, Inc. Stockholders that a Shareholder Filed a Class Action Against MRNA
August 14, 2024
From
Robbins LLP
Via
Business Wire
Stockholder Alert: Robbins LLP Informs Moderna, Inc. Stockholders that a Shareholder Filed a Class Action Against MRNA
August 14, 2024
From
Robbins LLP
Via
GlobeNewswire
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 14, 2024
From
Schall Law
Via
GlobeNewswire
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
June 07, 2024
Via
ACCESSWIRE
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
August 12, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Via
MarketBeat
Exposures
COVID-19
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 10, 2024
From
The Schall Law Firm
Via
Business Wire
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024
Via
ACCESSWIRE
MRNA Investors Have Opportunity to Join Moderna, Inc. Fraud Investigation with the Schall Law Firm
August 01, 2024
From
The Schall Law Firm
Via
Business Wire
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
July 10, 2024
Via
ACCESSWIRE
Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
July 08, 2024
Via
ACCESSWIRE
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
July 02, 2024
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
July 02, 2024
Via
ACCESSWIRE
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
June 28, 2024
Via
ACCESSWIRE
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
June 17, 2024
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Via
MarketBeat
Exposures
COVID-19
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
June 13, 2024
Via
ACCESSWIRE
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 10, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
June 10, 2024
Via
ACCESSWIRE
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
Novavax Stock’s Recent Surge and Future Potential
June 06, 2024
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance.
Via
MarketBeat
Topics
Economy
Exposures
COVID-19
Product Safety
Supply Chain
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
June 06, 2024
Via
ACCESSWIRE
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
June 03, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.